A Phase II Multi-Arm (Basket) Trial Investigating the Safety and Efficacy of IO102-IO103 in Combination With Pembrolizumab, as First-Line Treatment for Patients With Metastatic NSCLC, SCCHN, or Metastatic mUBC
NCT05077709 · COMPLETED · Phase 2
We track 1 ClinicalTrials.gov studies led by Io Biotech. The portfolio skews toward Phase 2 (1 trials).
1 clinical trials sponsored by Io Biotech.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
Io Biotech currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 2.
Io Biotech conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.